US20020193730A1 - Intrapulmonary delivery of polypeptide growth factors and cytokines - Google Patents
Intrapulmonary delivery of polypeptide growth factors and cytokines Download PDFInfo
- Publication number
- US20020193730A1 US20020193730A1 US10/171,562 US17156202A US2002193730A1 US 20020193730 A1 US20020193730 A1 US 20020193730A1 US 17156202 A US17156202 A US 17156202A US 2002193730 A1 US2002193730 A1 US 2002193730A1
- Authority
- US
- United States
- Prior art keywords
- polypeptide
- particles
- tumor necrosis
- necrosis factor
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
Definitions
- This invention relates to the administration of proteins by adsorption from the lungs.
- it is concerned with providing therapeutic, sustained doses of growth hormones or cytokines to the bloodstream without irritating or otherwise damaging lung tissue.
- Bensch et al. (“Yale J. Biol. Med.” 43:236-241 [1971]) later observed (based on similar studies with HRP) that macromolecules may cross the air-blood barrier by being transported directly into the pulmonary capillary blood in the pinocytotic vesicles of the membranous pneumocyte and endothelial cells.
- HRP horseradish protein
- U.S. Pat. No. 4,476,116 proposes delivering human growth hormone or interferon by intranasal absorption of a nasal spray containing the protein and a chelating agent. Since particles of 5 mm or greater are removed in the nasopharyngeal region (Juliano et al.) it must be concluded that an effective nasal spray would contain aerosol particles having at least this mean diameter.
- EP 122036 describes a powdered composition for intranasal administration of growth hormone or interferon wherein at least 90% of the particles had an effective diameter of 10 to 250 microns. The minimum diameter was established with the object to avoid introducing the particles into the lungs.
- Intranasal administration of growth hormone or interferons is undesirable because of dosage variability, side effects such as nasal irritation, extremely poor polypeptide permeability into the blood stream and polypeptide degradation by normal nasal microorganisms.
- these polypeptides have been conventionally administered by injection or infusion. This delivery route suffers from obvious deficiencies, the most glaring being the requirement for regular growth hormone injections in children or, in the case of interferons being employed for the treatment of malignancies, an absence of a healthy vasculature for catheterization of the patients. An improved method for the administration of these proteins is needed.
- the foregoing objects are accomplished by providing a method for delivering to the blood stream of a patient a therapeutic dose of a polypeptide selected from the group of growth factors and cytokines, which method comprises delivering a therapeutically effective dose of the polypeptide into the lungs of the patient.
- a device for accomplishing this method that comprises reservoir means for storing the polypeptide; a therapeutic dosage form of the polypeptide disposed in the reservoir means; dispersing means for forming in a gas a suspension of particles comprising the polypeptide wherein the size of the particles is sufficiently small to permit their penetration into the alveoli of the patient's lungs upon inhalation; means for transporting the polypeptide to the dispersing means; and means for delivering the particle suspension to alveoli of the patient's lungs.
- An advantage with respect to the delivery of therapeutic doses of these particular polypeptides is that they are delivered systemically by pulmonary absorption without pathological effects on the lungs or a requirement for an epithelial irritant or absorption enhancing agent such as ether, zinc oxide, antigens, histamine, methacholine, water soluble amphophilic steroids, bile salts such as sodium glycocholate, lower alkyl ethers of cellulose, chelating agents or water absorbing-water insoluble substances such as polyvinyl pyrrolidone, sodium carboxymethyl cellulose, polyacrylates and the like.
- an epithelial irritant or absorption enhancing agent such as ether, zinc oxide, antigens, histamine, methacholine, water soluble amphophilic steroids, bile salts such as sodium glycocholate, lower alkyl ethers of cellulose, chelating agents or water absorbing-water insoluble substances such as polyvinyl pyrrolidone, sodium carboxymethyl
- FIG. 1 is a schematic depiction of a device for intrapulmonary delivery of a polypeptide aerosol.
- FIG. 2 depicts the serum hGH concentrations following fine aerosol intrapulmonary delivery of methionyl human growth hormone to an anesthetized baboon. Two doses of 60 mg each are shown as D 1 and D 2 . Each dosing was terminated at the points designated “End D 1 ” and “End D 2 ”. Serum growth hormone concentrations increased rapidly and additively after each administration.
- FIGS. 3 and 4 show the serum concentrations of human gamma interferon and tumor necrosis factor-a after intratracheal instillation thereof into anesthetized rats. The intratracheal dose is shown below each graph.
- the polypeptides to be delivered by intrapulmonary absorption are growth factors and cytokines.
- Growth factors or hormones are polypeptides that induce the proliferation or enlargement of target cells. Such factors or hormones, hereafter referred to as hormones for convenience, may incidentally increase the respiratory rate or metabolism of the target cells, but in the absence of increased cell mitosis or enlargement a polypeptide is not to be considered a growth hormone for the purposes of this application.
- Most growth hormones exhibit a molecular weight of about from 5 kD to 75 kD and a pI ranging from about 4 to 8.
- growth hormone thymosin
- somatomedins such as IGF-1 or IGF-2
- transforming growth factors-a and b nerve growth factor, platelet-derived growth factor, ovarian growth factor, fibroblast growth factor, myoblast growth factor, epidermal growth factor and the like, but excluding insulin.
- IGF-1 or IGF-2 growth hormone
- transforming growth factors-a and b nerve growth factor
- platelet-derived growth factor ovarian growth factor
- fibroblast growth factor fibroblast growth factor
- myoblast growth factor myoblast growth factor
- epidermal growth factor epidermal growth factor and the like
- Cytokines are the polypeptide secretory products of cells constituting the immune system, e.g. lymphocytes such as B-cells and T cells, including helper and suppressor T cells, macrophages and neutrophils. Cytokines serve as effectors in that they induce changes in the activity or secretory products of other immune cells, or as direct acting proteins in that they induce a change in a target non-immune cell. Furthermore, many cytokines, e.g. thymosin or gamma interferon, may be considered growth hormones as well in that they induce the proliferation of specialized immune target cells.
- cytokines typically have molecular weights of about from 5 kD to 30 kD and pI of about from 4 to 8.
- examples of cytokines include the interleukins, tumor necrosis factors, interferons and immune suppressor factors.
- Preferred cytokines for use herein are tumor necrosis factors-a and b, and interferons-a, b and g.
- growth hormone and cytokine are to be considered to include amino acid sequence, glycosylation and other variants of the native molecules. These variants may exhibit enhanced levels of the normal biological activity of the native molecules or may, on the contrary, act antagonistically towards the native molecule. Alternatively, variants are selected for improved characteristics such as stability to oxidation, extended biological half-life, and the like. Such variants as are known or will be developed in the future are suitable for use herein.
- N-terminal methionyl human growth hormone (somatrem) is an example of a common variant produced in recombinant cell culture wherein a methionine residue not found in the native analogue is covalently bound to the normal N-terminal amino acid residue.
- polypeptides administered in accordance with this invention are first placed into a particulate dispersed form. This is accomplished by preparing an aqueous aerosol or solid particles which contain the polypeptide. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the desired polypeptide together with conventional pharmaceutically acceptable carriers and stabilizers.
- the carriers and stabilizers will vary depending upon the requirements for each polypeptide, but typically include nonionic surfactants (Tweens, Pluronics or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
- the formulations also can include mucolytic agents such as those described in U.S. Pat. No. 4,132,803, as well as bronchodilating agents.
- the formulations will be sterile. Aerosols generally will be prepared from isotonic solutions.
- the particles optionally include normal lung surfactant proteins.
- aerosols of particles in aqueous or nonaqueous, e.g. fluorocarbon propellant, suspension include, for example, intramolecular aggregates of the polypeptides or liposomal or microcapsular-entrapped polypeptides.
- the aerosols should be free of lung irritants, i.e. substances which cause acute bronchoconstriction, coughing, pulmonary edema or tissue destruction.
- nonirritating absorption enhancing agents are suitable for use herein.
- Sonic nebulizers preferably are used in preparing aerosols. Sonic nebulizers minimize exposing the polypeptides to shear, which can result in degradation of the molecule.
- a suitable device is the Bird Micronebulizer.
- Particulate aerosol suspensions are essentially fine dry powders containing the polypeptides. They are prepared by any number of conventional procedures. The simplest method of producing them is to micronize polypeptide, e.g. crystals or lyophilization cakes, and suspend the particles in dry fluorocarbon propellants. In these formulations the polypeptides do not dissolve in the hydrophobic propellants (which evaporate after the suspension is released from the pressurized device into the air). Rather, the polypeptides are suspended in the fluorocarbon. In an alternate embodiment the polypeptides are stored in a compartment separate from the propellant. Discharge of the propellant withdraws a predetermined dose from the storage compartment. The devices used to deliver drugs in this manner are known as metered dose inhalers (MDIs) (P. R. Byron, 1986, “Drug Development and Industrial Pharmacy” 12:993).
- MDIs metered dose inhalers
- the size of the aerosols or particles generally will range about from 0.5 mm to 4 mm, preferably about 0.5 to 1 mm. Smaller particles are less acceptable because they tend not to be deposited but instead are exhaled. Larger particles are not preferred because in large measure are unable to be deposited at the level of the alveoli, being removed by impaction within the nasopharyngeal or oral cavities (Byron, 1986, “J. Pharm. Sci.” 75:433). obviously, most aerosol or particulate compositions will be heterogenous in size distribution, although heterogeneity can be reduced by known methods, e.g. the screening unit described in EP 135390A.
- the proportion of particles having an average mean diameter in excess of about 4 mm is so large as to impair the delivery of a therapeutic dose by pulmonary inhalation.
- Suspensions containing greater than about 15% of particles within the 0.5-4 mm range can be used, but generally the proportion of particles having an average mean diameter larger than 4 mm should be less than about 25%, and preferably not greater than 10%, of the total number of particles.
- the diameters recited refer to the particle diameters as introduced into the respiratory tract.
- the particles may or may not bear a net charge.
- the presence of a net charge is desirable for minimizing particle aggregation in the airways since the particles will repel one another electrostatically.
- Charged particles are made by removing water from solutions of the polypeptides at a pH other than the isoelectric point, e.g. ordinarily about from 0.5 to 2 pH units on either side of the isoelectric point.
- dewatering of polypeptides at a pH other than the isoelectric point may result in precipitation or denaturation of the protein, so the desirability of use of such a pH will depend upon the known characteristics of the polypeptide to be administered.
- FIG. 1 A suitable system for inhalation delivery of the polypeptides herein is illustrated in FIG. 1.
- a source of compressed air 1 communicates with a nebulizer shown generally at 4 by way of a conduit 2 .
- the flow of compressed air is controlled by valve 3 .
- the nebulizer 4 contains a capillary tube 7 which extends down into the solution of growth hormone or cytokine in reservoir 8 .
- the end of capillary 7 which is distal to solution reservoir 8 terminates immediately adjacent to the orifice 5 of conduit 2 .
- An impaction sphere 6 is adjustably positioned opposite orifice 5 .
- the orifice 5 , capillary 7 and sphere 6 serve as the dispersing means for forming the aerosol of the polypeptide disposed in reservoir 8 .
- Nebulizer 4 also includes serrated output baffles shown generally at 9 , downstream of which is a conduit 10 communicating with a respirator mouthpiece 12 for sealably engaging the mouth of the patient (not shown).
- the passage of aerosol 15 through conduit 10 is controlled by valve 11 , which also operates valve 3 through circuit 13 and control device 14 .
- compressed air is valved by valve 3 on demand as determined by programmed control device 14 .
- the control device is actuated on demand from valve 11 .
- Compressed air passes through conduit 2 and out the orifice 5 .
- the flow of air over the end of capillary 7 draws the solution of polypeptide from reservoir 8 into the stream of air where, together with collision on the impaction sphere 6 , an aerosol of the solution is formed.
- the stable aerosol suspension is forced out by air pressure through baffles 9 and down conduit 10 upon demand from valve 11 as activated by the patient.
- the baffles are selected of appropriate size, dimension and composition to remove the bulk of particles greater than about 4 mm.
- the seating of mouthpiece 12 will ensure that the patient inhales substantially only the delivered mixture of air and aerosolized polypeptide with each breath.
- the animal was allowed to exhale normally after each ventilated breath and was positioned supine for dosing. After the first dosing period the animal was allowed to breathe normally for another 20 minutes, after which a second dosing was performed in the same way as the first. Blood plasma samples were taken at the initiation time of the first dose and thereafter as shown by the data points in FIG. 2. The baboon completely emerged from anesthesia 8 hours after the last pentobarbital injection. Radioimmunoassays of met-hGH in these sera showed that intrapulmonary delivery in accord herewith produced a blood level that is greater than twice that which is considered an acceptable therapeutic dose when administered intramuscularly.
- the radioimmunoassay employed in this example also will cross-react with normal baboon growth hormone, so it is believed that some of the hGH detected at 28 hours after the commencement of dosing may represent a circadian or stress induced increase in baboon growth hormone, probably similar to the levels in rhesus monkeys (10 ng/ml). Since the normal detectable GH levels in primates typically fall within the 10-20 mg/ml range, the method of this invention made it possible to deliver far in excess of a systemic therapeutically effective dose of hGH for a period exceeding 28 hours. This was particularly surprising since the general view is that long term drug delivery (>12 hr) is not achievable by intrapulmonary inhalation (Byron, op cit. ).
Abstract
Polypeptides selected from the group of growth factors and cytokines are administered by intrapulmonary inhalation. Disclosed are novel compositions and devices for effecting the intrapulmonary administration of these polypeptides.
Description
- This invention relates to the administration of proteins by adsorption from the lungs. In particular, it is concerned with providing therapeutic, sustained doses of growth hormones or cytokines to the bloodstream without irritating or otherwise damaging lung tissue.
- Drug delivery by pulmonary absorption from particles such as aerosols has met with considerable success in several instances of localized delivery to lungs as the drug target tissue, most notably the use of beta adrenergic antagonists in the treatment of asthma. Other drugs that have been administered in this fashion include corticosteroids and cromolyn sodium. On the other hand, the administration of aminoglycoside antibiotics, antiviral drugs and anticancer drugs for systemic action by this route has only met with spotty success. In some cases, lack of delivery to the blood stream was attributed to inability of the drug to pass through the alveolar epithelium. In other cases the drug was found to be irritating and bronchoconstrictive (Juliano, 1984, “Pharm. Ther.”, 24:355-365). At this time it is not possible to reasonably predict in advance that any given drug will be nonirritating or will be adsorbed through the lungs in an amount sufficient to be therapeutically useful.
- Similarly, extensive studies have been conducted on the pulmonary absorption of proteins and polypeptides. While size, lipophobicity, and possibly other poorly characterized features of such molecules appear to create a substantial barrier to their absorption into the blood stream (Juliano,op cit; Egan, 1983, “Am. Rev. Resp. Dis.” 127(5) Pt. 2 537-539; Hogg et al., 1979, “Fed. Proc.” 38(2):197-201), there remains considerable disagreement about protein permeability from the alveoli into the blood under ordinary conditions. For example, studies with albumin or horse radish peroxidase (HRP) are illustrative.
- Dominguez et al. (“Lab. Invest.” 16(6):905 [l967]) observe that the alveolar wall is only “slightly permeable” to albumin. Similarly, earlier workers found no pulmonary absorption of homologous plasma albumin at all (Drinker et al., 1947 “J. Exp. Med.” 86:7), while others demonstrated absorption of albumin only from lung subsections hyperinflated in excess of 40 cm H2O pressure; the same pressure applied to the total lung did not produce protein permeability (Egan et al., 1982, “J. Appl. Physiol.” 53:121). Newborn lambs were found to be capable of pulmonary albumin absorption, but only for a brief period postpartum (Egan et al., 1984, “Ped. Res.” 18(6):566). Finally, Bensch et al. (“Science” 157:1204-1206 [1967]) report the rapid absorption of instilled solutions of radioactively labelled albumin or gamma globulin across the pulmonary air-tissue barrier. More than two thirds of the administered polypeptides could be accounted for in the blood of the test animals after 24 hours. These authors also report the work of others (Drinker et al., op cit) to the effect that removal of lower molecular weight proteins from the lumin of the alveoli occurs only after degradation of the molecules, notwithstanding that Bensch et al. did not detect degradation of albumin or gamma globulin.
- Bensch et al. (“Yale J. Biol. Med.” 43:236-241 [1971]) later observed (based on similar studies with HRP) that macromolecules may cross the air-blood barrier by being transported directly into the pulmonary capillary blood in the pinocytotic vesicles of the membranous pneumocyte and endothelial cells. However, the Bensch et al. experiments were conducted by instilling HRP into the lungs in the form of an aqueous solution.
- Conner et al. (“Fundamental and Appl. Toxicology” 5:99-104 [1985]) instilled a solution of HRP into the trachea of experimental animals after exposure to zinc oxide particles, suggesting that absorption of this protein was a function of pathological effects by zinc oxide. This was consistent with the report by Hogg et al.,op cit. that the bronchial epithelium is normally nonpermeable to proteins unless damaged in some way, such as by cigarette smoke, ether, antigens, histamine, or methacholine.
- Other polypeptide probes besides albumin, gamma globulin and HRP have been used in the study of pulmonary absorption. These include microperoxidase, equine cytochrome c, equine myoglobin, bovine lactoperoxidase and human myeloperoxidase (Schneeberger, 1978, “Fed. Proc.” 37(11):2471), superoxide dismutase or catalase (Padmanabhan et al., 1985, “Am. Rev. Respir. Dis.” 132 (1):164-167), and ferritin (Richardson et al., 1976, “Lab. Invest.” 35(4):307). None of these agents, however, has been employed in a systemic therapeutic context, i.e. delivered in the expectation of achieving a therapeutic dosage at a desired site distal from the lungs per se.
- U.S. Pat. No. 4,476,116 proposes delivering human growth hormone or interferon by intranasal absorption of a nasal spray containing the protein and a chelating agent. Since particles of 5 mm or greater are removed in the nasopharyngeal region (Juliano et al.) it must be concluded that an effective nasal spray would contain aerosol particles having at least this mean diameter. Similarly, EP 122036 describes a powdered composition for intranasal administration of growth hormone or interferon wherein at least 90% of the particles had an effective diameter of 10 to 250 microns. The minimum diameter was established with the object to avoid introducing the particles into the lungs.
- Intranasal administration of growth hormone or interferons is undesirable because of dosage variability, side effects such as nasal irritation, extremely poor polypeptide permeability into the blood stream and polypeptide degradation by normal nasal microorganisms. Of course, these polypeptides have been conventionally administered by injection or infusion. This delivery route suffers from obvious deficiencies, the most glaring being the requirement for regular growth hormone injections in children or, in the case of interferons being employed for the treatment of malignancies, an absence of a healthy vasculature for catheterization of the patients. An improved method for the administration of these proteins is needed.
- Accordingly, it is an object herein to obviate the need for injections or infusions of certain polypeptides.
- It is a further object herein to reduce the frequency of administration of certain polypeptides by providing sustained release from pulmonary tissue.
- It is another object to deliver therapeutically effective doses of certain polypeptides without therapeutically significant degradation of the polypeptides or the use of agents that lead to irritation of the bronchi, apithelium or other pulmonary tissue.
- These and other objects of the invention will be apparent to the ordinary artisan from the specification as a whole.
- The foregoing objects are accomplished by providing a method for delivering to the blood stream of a patient a therapeutic dose of a polypeptide selected from the group of growth factors and cytokines, which method comprises delivering a therapeutically effective dose of the polypeptide into the lungs of the patient. A device is provided for accomplishing this method that comprises reservoir means for storing the polypeptide; a therapeutic dosage form of the polypeptide disposed in the reservoir means; dispersing means for forming in a gas a suspension of particles comprising the polypeptide wherein the size of the particles is sufficiently small to permit their penetration into the alveoli of the patient's lungs upon inhalation; means for transporting the polypeptide to the dispersing means; and means for delivering the particle suspension to alveoli of the patient's lungs.
- An advantage with respect to the delivery of therapeutic doses of these particular polypeptides is that they are delivered systemically by pulmonary absorption without pathological effects on the lungs or a requirement for an epithelial irritant or absorption enhancing agent such as ether, zinc oxide, antigens, histamine, methacholine, water soluble amphophilic steroids, bile salts such as sodium glycocholate, lower alkyl ethers of cellulose, chelating agents or water absorbing-water insoluble substances such as polyvinyl pyrrolidone, sodium carboxymethyl cellulose, polyacrylates and the like.
- FIG. 1 is a schematic depiction of a device for intrapulmonary delivery of a polypeptide aerosol.
- FIG. 2 depicts the serum hGH concentrations following fine aerosol intrapulmonary delivery of methionyl human growth hormone to an anesthetized baboon. Two doses of 60 mg each are shown as D1 and D2. Each dosing was terminated at the points designated “End D1” and “End D2”. Serum growth hormone concentrations increased rapidly and additively after each administration.
- FIGS. 3 and 4 show the serum concentrations of human gamma interferon and tumor necrosis factor-a after intratracheal instillation thereof into anesthetized rats. The intratracheal dose is shown below each graph.
- The polypeptides to be delivered by intrapulmonary absorption are growth factors and cytokines. Growth factors or hormones are polypeptides that induce the proliferation or enlargement of target cells. Such factors or hormones, hereafter referred to as hormones for convenience, may incidentally increase the respiratory rate or metabolism of the target cells, but in the absence of increased cell mitosis or enlargement a polypeptide is not to be considered a growth hormone for the purposes of this application. Most growth hormones exhibit a molecular weight of about from 5 kD to 75 kD and a pI ranging from about 4 to 8. Specific examples include growth hormone (somatropin), thymosin, somatomedins such as IGF-1 or IGF-2, transforming growth factors-a and b, nerve growth factor, platelet-derived growth factor, ovarian growth factor, fibroblast growth factor, myoblast growth factor, epidermal growth factor and the like, but excluding insulin. These substances are well known to those skilled in the art and, in many cases, have been cloned and expressed in recombinant organisms. The preferred growth hormone for use herein is somatropin or its N-terminal methionylated variant (somatrem) described below.
- Cytokines are the polypeptide secretory products of cells constituting the immune system, e.g. lymphocytes such as B-cells and T cells, including helper and suppressor T cells, macrophages and neutrophils. Cytokines serve as effectors in that they induce changes in the activity or secretory products of other immune cells, or as direct acting proteins in that they induce a change in a target non-immune cell. Furthermore, many cytokines, e.g. thymosin or gamma interferon, may be considered growth hormones as well in that they induce the proliferation of specialized immune target cells. Typically, cytokines have molecular weights of about from 5 kD to 30 kD and pI of about from 4 to 8. Examples of cytokines include the interleukins, tumor necrosis factors, interferons and immune suppressor factors. Preferred cytokines for use herein are tumor necrosis factors-a and b, and interferons-a, b and g.
- The terms growth hormone and cytokine are to be considered to include amino acid sequence, glycosylation and other variants of the native molecules. These variants may exhibit enhanced levels of the normal biological activity of the native molecules or may, on the contrary, act antagonistically towards the native molecule. Alternatively, variants are selected for improved characteristics such as stability to oxidation, extended biological half-life, and the like. Such variants as are known or will be developed in the future are suitable for use herein. For example, N-terminal methionyl human growth hormone (somatrem) is an example of a common variant produced in recombinant cell culture wherein a methionine residue not found in the native analogue is covalently bound to the normal N-terminal amino acid residue.
- The polypeptides administered in accordance with this invention are first placed into a particulate dispersed form. This is accomplished by preparing an aqueous aerosol or solid particles which contain the polypeptide. Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the desired polypeptide together with conventional pharmaceutically acceptable carriers and stabilizers. The carriers and stabilizers will vary depending upon the requirements for each polypeptide, but typically include nonionic surfactants (Tweens, Pluronics or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. The formulations also can include mucolytic agents such as those described in U.S. Pat. No. 4,132,803, as well as bronchodilating agents. The formulations will be sterile. Aerosols generally will be prepared from isotonic solutions. The particles optionally include normal lung surfactant proteins.
- It is within the scope of this invention to form aerosols of particles in aqueous or nonaqueous, e.g. fluorocarbon propellant, suspension. Such particles include, for example, intramolecular aggregates of the polypeptides or liposomal or microcapsular-entrapped polypeptides. The aerosols should be free of lung irritants, i.e. substances which cause acute bronchoconstriction, coughing, pulmonary edema or tissue destruction. However, nonirritating absorption enhancing agents are suitable for use herein.
- Sonic nebulizers preferably are used in preparing aerosols. Sonic nebulizers minimize exposing the polypeptides to shear, which can result in degradation of the molecule. A suitable device is the Bird Micronebulizer. However, it is also within the scope of this invention to employ other atomizing or nebulizing systems or intratracheal delivery systems, e.g. U.S. Pat. No. 3,915,165, the aerosol generator-inhalator described in EP 166476, the jet nebulizers described by Newman et al. “Thorax” 40(9):671-676 (1985), metered dose inhalers (M. Berenberg, 1985, “J. Asthma-USA” 22(2):87-92), or other devices (Sears et al., 1983 “N.Z. Med. J.” 96:743II; O'Reilly et al., 1983, “Br. Med. J.” 286:6377; or J. Stander et al., 1982, “Respiration” 44(3):237-240), so long as they are compatible with the protein to be administered and are capable of delivering particles of the desired size.
- Particulate aerosol suspensions are essentially fine dry powders containing the polypeptides. They are prepared by any number of conventional procedures. The simplest method of producing them is to micronize polypeptide, e.g. crystals or lyophilization cakes, and suspend the particles in dry fluorocarbon propellants. In these formulations the polypeptides do not dissolve in the hydrophobic propellants (which evaporate after the suspension is released from the pressurized device into the air). Rather, the polypeptides are suspended in the fluorocarbon. In an alternate embodiment the polypeptides are stored in a compartment separate from the propellant. Discharge of the propellant withdraws a predetermined dose from the storage compartment. The devices used to deliver drugs in this manner are known as metered dose inhalers (MDIs) (P. R. Byron, 1986, “Drug Development and Industrial Pharmacy” 12:993).
- The size of the aerosols or particles generally will range about from 0.5 mm to 4 mm, preferably about 0.5 to 1 mm. Smaller particles are less acceptable because they tend not to be deposited but instead are exhaled. Larger particles are not preferred because in large measure are unable to be deposited at the level of the alveoli, being removed by impaction within the nasopharyngeal or oral cavities (Byron, 1986, “J. Pharm. Sci.” 75:433). obviously, most aerosol or particulate compositions will be heterogenous in size distribution, although heterogeneity can be reduced by known methods, e.g. the screening unit described in EP 135390A. Heterogeneity will not be disadvantageous unless the proportion of particles having an average mean diameter in excess of about 4 mm is so large as to impair the delivery of a therapeutic dose by pulmonary inhalation. Suspensions containing greater than about 15% of particles within the 0.5-4 mm range can be used, but generally the proportion of particles having an average mean diameter larger than 4 mm should be less than about 25%, and preferably not greater than 10%, of the total number of particles. The diameters recited refer to the particle diameters as introduced into the respiratory tract.
- The particles may or may not bear a net charge. The presence of a net charge is desirable for minimizing particle aggregation in the airways since the particles will repel one another electrostatically. Charged particles are made by removing water from solutions of the polypeptides at a pH other than the isoelectric point, e.g. ordinarily about from 0.5 to 2 pH units on either side of the isoelectric point. on the other hand, dewatering of polypeptides at a pH other than the isoelectric point may result in precipitation or denaturation of the protein, so the desirability of use of such a pH will depend upon the known characteristics of the polypeptide to be administered.
- A suitable system for inhalation delivery of the polypeptides herein is illustrated in FIG. 1. A source of
compressed air 1 communicates with a nebulizer shown generally at 4 by way of aconduit 2. The flow of compressed air is controlled byvalve 3. Thenebulizer 4 contains acapillary tube 7 which extends down into the solution of growth hormone or cytokine inreservoir 8. The end ofcapillary 7 which is distal tosolution reservoir 8 terminates immediately adjacent to theorifice 5 ofconduit 2. Animpaction sphere 6 is adjustably positionedopposite orifice 5. Theorifice 5,capillary 7 andsphere 6 serve as the dispersing means for forming the aerosol of the polypeptide disposed inreservoir 8.Nebulizer 4 also includes serrated output baffles shown generally at 9, downstream of which is aconduit 10 communicating with arespirator mouthpiece 12 for sealably engaging the mouth of the patient (not shown). The passage ofaerosol 15 throughconduit 10 is controlled byvalve 11, which also operatesvalve 3 throughcircuit 13 andcontrol device 14. - In operation, compressed air is valved by
valve 3 on demand as determined by programmedcontrol device 14. The control device is actuated on demand fromvalve 11. Compressed air passes throughconduit 2 and out theorifice 5. The flow of air over the end ofcapillary 7 draws the solution of polypeptide fromreservoir 8 into the stream of air where, together with collision on theimpaction sphere 6, an aerosol of the solution is formed. The stable aerosol suspension is forced out by air pressure throughbaffles 9 and downconduit 10 upon demand fromvalve 11 as activated by the patient. The baffles are selected of appropriate size, dimension and composition to remove the bulk of particles greater than about 4 mm. The seating ofmouthpiece 12 will ensure that the patient inhales substantially only the delivered mixture of air and aerosolized polypeptide with each breath. - The method herein is illustrated by way of the following examples, which are not to be construed as limiting the invention.
- An adult baboon weighing 24 kg was anesthetized with intravenous pentobarbital, a tracheal intubation performed and the animal allowed to breathe normally until and between dosing. A Bird Micronebulizer in line with a
Bird Mark 7 respirator was charged with 5-10 ml of a solution of 12 mg/ml ProtropinR brand of met-hGH (somatrem) in mannitol/phosphate buffer. The Micronebulizer then was used to simultaneously ventilate and dose the animal at 22 cm H2O at a rate of 1.8 mg/hGH/-min. for 30 min. At this pressure the animal ventilated at approximately normal inspiratory volume. The animal was allowed to exhale normally after each ventilated breath and was positioned supine for dosing. After the first dosing period the animal was allowed to breathe normally for another 20 minutes, after which a second dosing was performed in the same way as the first. Blood plasma samples were taken at the initiation time of the first dose and thereafter as shown by the data points in FIG. 2. The baboon completely emerged fromanesthesia 8 hours after the last pentobarbital injection. Radioimmunoassays of met-hGH in these sera showed that intrapulmonary delivery in accord herewith produced a blood level that is greater than twice that which is considered an acceptable therapeutic dose when administered intramuscularly. The radioimmunoassay employed in this example also will cross-react with normal baboon growth hormone, so it is believed that some of the hGH detected at 28 hours after the commencement of dosing may represent a circadian or stress induced increase in baboon growth hormone, probably similar to the levels in rhesus monkeys (10 ng/ml). Since the normal detectable GH levels in primates typically fall within the 10-20 mg/ml range, the method of this invention made it possible to deliver far in excess of a systemic therapeutically effective dose of hGH for a period exceeding 28 hours. This was particularly surprising since the general view is that long term drug delivery (>12 hr) is not achievable by intrapulmonary inhalation (Byron, op cit.). - Adult rats were anesthetized and tracheal intubations performed on each animal. Solutions of human recombinant gamma interferon and human recombinant tumor necrosis factor were injected into the trachea of test animals until a dosage of 3 mg/Kg and 378 mcg/Kg, respectively, was delivered. Serum samples were withdrawn from each test animal at the times indicated in FIGS.3-4 and assayed for the appropriate polypeptide. The results, shown in FIGS. 3-4, clearly demonstrate effective system delivery of these two cytokines.
Claims (16)
1. A device for delivering to the blood stream of a patient a therapeutic dose of a polypeptide selected from the group of growth factors or cytokines, said device comprising reservoir means for storing the polypeptide; a therapeutic dosage form of the polypeptide disposed in the reservoir means; dispersing means for forming in a gas a suspension of particles comprising the polypeptide wherein the size of the particles is sufficiently small to permit their penetration into the alveoli of the patient's lungs upon inhalation; means for transporting the polypeptide to the dispersing means and means for delivering the particle suspension to the alveoli of the patient's lungs.
2. The device of claim 1 wherein the dispersing means is capable of producing particles having a size of about from 0.5 mm to 4 mm.
3. The device of claim 1 wherein the polypeptide is somatropin, somatrem, interleukin 1, interleukin 2, tumor necrosis factor-a, tumor necrosis factor-b, a combination of tumor necrosis factor-a or tumor necrosis factor-b plus an interferon; or a combination of an interferon and interleukin-2.
4. The device of claim 1 wherein the dispersing means is a means for hydraulic atomization or means for ultrasonic dispersion.
5. The device of claim 1 wherein the reservoir means is capable of containing an aqueous solution of the polypeptide.
6. The device of claim 1 wherein the reservoir means is capable of containing a powder comprising the polypeptide suspended in a dry fluorocarbon.
7. The device of claim 1 wherein the means for delivering the suspension to the alveoli is a mouthpiece for sealably engaging the oral cavity.
8. A method for delivering to the blood stream of a patient a therapeutic dose of a polypeptide selected from the group of growth factors and cytokines comprising delivering a therapeutically effective dose of the polypeptide into the lungs of the patient.
9. The method of claim 8 wherein the polypeptide is somatropin, somatrem, interleukin 1, interleukin 2, tumor necrosis factor-a, tumor necrosis factor-b, a combination of tumor necrosis factor-a or tumor necrosis factor-b plus an interferon; or a combination of an interferon and interleukin-2.
10. The method of claim 8 wherein the polypeptide is unaccompanied by an absorption enhancing agent.
11. The method of claim 8 wherein the polypeptide is present in particulates having a mean average diameter of about from 0.5 to 4 mm.
12. The method of claim 11 wherein the particulates are an aerosol of an aqueous solution of the polypeptide.
13. The method of claim 8 wherein the dose is delivered into the alveoli of the lungs without substantial contact with the nasal passages.
14. A dispersion of polypeptide containing particles wherein greater than about 15% of the particles have a mean average diameter of about from 0.5 to 4 mm and wherein the polypeptide is selected from a therapeutically effective dosage of a growth factor or cytokine.
15. The dispersion of claim 14 wherein the particles contain an aqueous solution of the polypeptide.
16. The dispersion of claim 15 wherein the dispersion is free of ether, antigens, histamines, zinc oxide, methacholine, amphophilic steroids, chelating agents, bile salts or water-absorbing water-insoluble polymers in amounts sufficient to
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/171,562 US20020193730A1 (en) | 1986-08-19 | 2002-06-10 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89796286A | 1986-08-19 | 1986-08-19 | |
US31232589A | 1989-02-16 | 1989-02-16 | |
US76203991A | 1991-09-17 | 1991-09-17 | |
US98226892A | 1992-11-25 | 1992-11-25 | |
US08/128,058 US6099517A (en) | 1986-08-19 | 1993-09-27 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US09/552,199 US6402733B1 (en) | 1986-08-19 | 2000-04-19 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US10/171,562 US20020193730A1 (en) | 1986-08-19 | 2002-06-10 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/552,199 Continuation US6402733B1 (en) | 1986-08-19 | 2000-04-19 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020193730A1 true US20020193730A1 (en) | 2002-12-19 |
Family
ID=25408720
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/128,058 Expired - Fee Related US6099517A (en) | 1986-08-19 | 1993-09-27 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US09/552,199 Expired - Fee Related US6402733B1 (en) | 1986-08-19 | 2000-04-19 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US10/171,562 Abandoned US20020193730A1 (en) | 1986-08-19 | 2002-06-10 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/128,058 Expired - Fee Related US6099517A (en) | 1986-08-19 | 1993-09-27 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US09/552,199 Expired - Fee Related US6402733B1 (en) | 1986-08-19 | 2000-04-19 | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Country Status (8)
Country | Link |
---|---|
US (3) | US6099517A (en) |
EP (1) | EP0257956B2 (en) |
JP (1) | JP2573959B2 (en) |
AT (1) | ATE76311T1 (en) |
CA (1) | CA1292182C (en) |
DE (1) | DE3779221D1 (en) |
ES (1) | ES2032831T5 (en) |
GR (1) | GR3005238T3 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030222364A1 (en) * | 2002-03-20 | 2003-12-04 | Jackson Blair C. | Method and apparatus for producing dry particles |
US20040009231A1 (en) * | 2002-03-20 | 2004-01-15 | Advanced Inhalation Research, Inc. | hGH (human growth hormone) formulations for pulmonary administration |
US20050163725A1 (en) * | 2002-03-20 | 2005-07-28 | Blizzard Charles D. | Method for administration of growth hormone via pulmonary delivery |
WO2006055950A1 (en) * | 2004-11-18 | 2006-05-26 | Nektar Therapeutics | Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents |
Families Citing this family (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3779221D1 (en) * | 1986-08-19 | 1992-06-25 | Genentech Inc | DEVICE AND DISPERSION FOR THE INTRAPULMONAL ENTERING OF POLYPEPTIDE GROWTH SUBSTANCES AND CYTOKINS. |
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
US4944941A (en) * | 1987-08-07 | 1990-07-31 | Genentech, Inc. | Methods and compositions for the treatment of lung conditions |
JP2739733B2 (en) * | 1988-08-09 | 1998-04-15 | オムロン株式会社 | Inhaler |
US5198212A (en) * | 1988-10-31 | 1993-03-30 | University Of Lousville Research Foundation Incorporated | Method and compositions for treatment of trauma-associated sepsis with gamma interferon |
EP0377174A3 (en) * | 1988-12-22 | 1990-11-22 | Büsselmann, Manfred | Method and apparatus for spraying and atomising liquids |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5011678A (en) * | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
JPH05963A (en) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
US5780012A (en) * | 1990-06-21 | 1998-07-14 | Huland; Edith | Method for reducing lung afflictions by inhalation of cytokine solutions |
DK0462305T3 (en) * | 1990-06-21 | 1995-04-24 | Huland Edith | Use of cytokine-containing aerosols as well as cytokine-containing aerosols per se |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
DE4117078A1 (en) * | 1991-05-25 | 1992-11-26 | Boehringer Ingelheim Kg | METHOD FOR PRODUCING THERAPEUTICALLY APPLICABLE AEROSOLS |
US6673335B1 (en) | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US7448375B2 (en) * | 1993-01-29 | 2008-11-11 | Aradigm Corporation | Method of treating diabetes mellitus in a patient |
US5354934A (en) † | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
IL109350A (en) * | 1993-05-12 | 2001-01-28 | Genentech Inc | Stable liquid compositions of gamma interferon |
US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
US5512269A (en) * | 1993-06-09 | 1996-04-30 | Burroughs Wellcome, Co. | Method of treating retained pulmonary secretions |
US20030113273A1 (en) * | 1996-06-17 | 2003-06-19 | Patton John S. | Methods and compositions for pulmonary delivery of insulin |
WO1995024183A1 (en) | 1994-03-07 | 1995-09-14 | Inhale Therapeutic Systems | Methods and compositions for pulmonary delivery of insulin |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
US5522385A (en) * | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US6428771B1 (en) * | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
US5972331A (en) * | 1995-12-22 | 1999-10-26 | Schering Corporation | Crystalline interferon alpha for pulmonary delivery and method for producing the same |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
ES2389387T3 (en) | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Homologous VEGF and BMP1 polypeptides |
SE9803770D0 (en) * | 1998-11-05 | 1998-11-05 | Astra Ab | Dry powder pharmaceutical formulation |
DE19851380A1 (en) * | 1998-11-07 | 2000-05-11 | Messer Griesheim Gmbh | Perfuming oxygen |
IL147029A0 (en) | 1999-06-28 | 2002-08-14 | Genentech Inc | Method for making apo-2 ligand using divalent metal ions |
EP2280004B1 (en) * | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
US9006175B2 (en) * | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
JP3852256B2 (en) | 1999-11-10 | 2006-11-29 | 富士ゼロックス株式会社 | Inkjet recording device |
JP2001187459A (en) | 1999-12-28 | 2001-07-10 | Fuji Xerox Co Ltd | Ink jet recorder |
US20010043906A1 (en) * | 1999-12-30 | 2001-11-22 | Vlasselaer Peter Van | gamma-IFN liquid-droplet aerosol and method |
WO2001051032A2 (en) * | 2000-01-14 | 2001-07-19 | Brown University Research Foundation | Micronized freeze-dried particles |
US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
CA2396796C (en) * | 2000-01-25 | 2011-06-21 | Aeropharm Technology, Inc. | Stabilized medicinal aerosol particulate formulations |
MXPA02001323A (en) | 2000-05-10 | 2004-07-16 | Alliance Pharma | Phospholipid-based powders for drug delivery. |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
DK2042597T3 (en) | 2000-06-23 | 2014-08-11 | Genentech Inc | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING ANGIOGENESIS |
CA2709771A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
JP2004515467A (en) * | 2000-08-07 | 2004-05-27 | ネクター セラピューティックス | Inhalable, spray-dried, 4-helix bundle protein powder with minimal aggregates |
JP4931282B2 (en) * | 2000-10-02 | 2012-05-16 | 日本ケミカルリサーチ株式会社 | Bioactive peptide-containing powder |
AU2002217880A1 (en) * | 2000-11-15 | 2002-05-27 | Scimed Life Systems, Inc. | Device and method for treating female urinary incontinence |
CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
AU2001298053A1 (en) * | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
CA2461292A1 (en) | 2001-10-02 | 2003-04-10 | Genentech, Inc. | Apo-2 ligand variants and uses thereof |
DK1450847T3 (en) | 2001-11-13 | 2010-12-13 | Genentech Inc | Apo2 ligand / TRAIL formulations and applications thereof |
CA2468958C (en) | 2001-12-19 | 2012-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
AU2002360018A1 (en) | 2001-12-27 | 2003-07-15 | Nsk Ltd. | Vehicle tilt type steering device |
US20040063912A1 (en) * | 2002-03-15 | 2004-04-01 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
RS20050008A (en) * | 2002-07-08 | 2007-06-04 | Pliva-Istraživački Institut D.O.O., | New compounds,compositions and methods for treatment of inflammatory diseases and conditions |
US7157433B2 (en) * | 2002-07-08 | 2007-01-02 | Glaxosmithkline Istrazivacki Centar Zagreb | Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules |
WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
US7338171B2 (en) * | 2003-10-27 | 2008-03-04 | Jen-Chuen Hsieh | Method and apparatus for visual drive control |
AU2005204378B2 (en) * | 2004-01-12 | 2009-01-22 | Mannkind Corporation | A method of reducing serum proinsulin levels in type 2 diabetics |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
ES2398838T3 (en) * | 2004-03-12 | 2013-03-22 | Biodel, Inc. | Fast-acting drug delivery compositions |
US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
JP5078014B2 (en) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | Catalytic reaction of diketopiperazine synthesis. |
MX2007002189A (en) | 2004-08-23 | 2008-01-11 | Mannkind Corp | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery. |
EP1805202B1 (en) | 2004-10-27 | 2009-12-30 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Conjugates with anti-inflammatory activity |
AP2334A (en) * | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
US7943634B2 (en) * | 2004-12-17 | 2011-05-17 | Glenmark Pharmaceuticals S.A. | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
US20070086952A1 (en) * | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
US7713929B2 (en) | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
IN2015DN00888A (en) | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
MX2008013165A (en) * | 2006-04-12 | 2009-01-29 | Biodel Inc | Rapid acting and long acting insulin combination formulations. |
GB0617417D0 (en) * | 2006-09-05 | 2006-10-18 | Concept 2 Manufacture Design L | A nebuliser valve |
WO2009089181A1 (en) * | 2008-01-04 | 2009-07-16 | Blodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
JP4654266B2 (en) * | 2008-05-14 | 2011-03-16 | 株式会社群馬コイケ | Nebulizer |
KR101933816B1 (en) | 2008-06-13 | 2019-03-29 | 맨카인드 코포레이션 | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
WO2009155581A1 (en) | 2008-06-20 | 2009-12-23 | Mannkind Corporation | An interactive apparatus and method for real-time profiling of inhalation efforts |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
AU2009291747B2 (en) | 2008-09-10 | 2016-05-26 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
EP2379585A2 (en) | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
EP2260857A1 (en) | 2009-06-11 | 2010-12-15 | Alfact Innovation | Novel applications of HIP/PAP or derivatives thereof |
BRPI1013154B1 (en) | 2009-06-12 | 2020-04-07 | Mannkind Corp | MICROPARTICLES OF DICETOPIPERAZINE WITH SPECIFIC SURFACE AREAS DEFINED, DRY POWDER UNDERSTANDING THE REFERRED MICROPARTICLES, METHOD FOR FORMATION OF THE REFERENCESMICROPARTICLES AND THE FORMATION OF MICROPARTYSTEMS |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
RU2707126C2 (en) | 2009-12-07 | 2019-11-22 | Пирис Аг | Human lipolocal 2 malletes (lcn2, hngal) with affinity for specific target |
MX359281B (en) | 2010-06-21 | 2018-09-21 | Mannkind Corp | Dry powder drug delivery system and methods. |
SG193313A1 (en) | 2011-03-10 | 2013-10-30 | Genentech Inc | Treatment of disorders with altered vascular barrier function |
MX353285B (en) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Blister package for pharmaceutical cartridges. |
CA2834776A1 (en) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
IN2014DN03093A (en) | 2011-10-24 | 2015-05-15 | Mannkind Corp | |
SG10201605800UA (en) | 2012-07-12 | 2016-09-29 | Mannkind Corp | Dry powder drug delivery system and methods |
EP2687225A1 (en) | 2012-07-19 | 2014-01-22 | Alfact Innovation | HIP/PAP protein and derivatives thereof for use in treating cancer |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
CA2918369C (en) | 2013-07-18 | 2021-06-29 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
CA2936611A1 (en) | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
CA2888068A1 (en) | 2014-04-15 | 2015-10-15 | The Hospital For Sick Children | Cationic antimicrobial peptides |
EP3789397B1 (en) | 2014-05-22 | 2023-12-06 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
WO2016120307A1 (en) | 2015-01-28 | 2016-08-04 | Pieris Ag | Novel proteins specific for angiogenesis |
BR112017020434A2 (en) | 2015-05-04 | 2018-06-26 | Pieris Pharmaceuticals Gmbh | fusion polypeptides, nucleic acid molecule, host cell, method for producing a fusion polypeptide, uses of fusion polypeptide, methods for activating signaling pathways, for costimulating cells, for inducing t lymphocyte proliferation, for directing assembly cd137, to induce a local t-cell response, to induce a local nk cell response, and to induce il-2 production |
MX2017014082A (en) | 2015-05-04 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137. |
KR20180008649A (en) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | The mutein of human lipocalin 2 with affinity for glypicane-3 (GPC3) |
DK3298030T3 (en) | 2015-05-18 | 2023-02-06 | Pieris Pharmaceuticals Gmbh | Anti-cancerfusionspolypeptid |
EP3383921A4 (en) | 2015-11-30 | 2019-04-17 | Pieris Australia Pty Ltd. | Novel anti-angiogenic fusion polypeptides |
TW201725212A (en) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | Novel proteins specific for calcitonin gene-related peptide |
WO2023111664A1 (en) * | 2021-12-19 | 2023-06-22 | Kamagtech Bio Pharma | Device and method for use in treatment of pathogens |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
US4590003A (en) * | 1984-03-23 | 1986-05-20 | Oncogen | Platelet related growth regulator |
US4613500A (en) * | 1983-03-09 | 1986-09-23 | Teijin Limited | Powdery pharmaceutical composition for nasal administration |
US4628045A (en) * | 1984-08-09 | 1986-12-09 | Immunetech Pharmaceuticals | Immunotherapeutic antiallergic polypeptide agents which bind to basophil immunoglobin Fc receptors |
US4645828A (en) * | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
US4659358A (en) * | 1985-03-19 | 1987-04-21 | Emhart Industries, Inc. | Mould arrangement of a glassware forming machine |
US4699136A (en) * | 1983-12-22 | 1987-10-13 | Krauser Robert S | Method and apparatus for treating ailments |
US4710305A (en) * | 1986-12-29 | 1987-12-01 | Conoco Inc. | Processes and oxidizing agents for oxidizing sulfide ion to innocuous, soluble sulfur species |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
US4771769A (en) * | 1982-12-20 | 1988-09-20 | Schering Corporation | Hand held metered spray dispenser |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US5284656A (en) * | 1991-03-15 | 1994-02-08 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
US6099517A (en) * | 1986-08-19 | 2000-08-08 | Genentech, Inc. | Intrapulmonary delivery of polypeptide growth factors and cytokines |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481191A (en) | 1983-03-30 | 1984-11-06 | The Regents Of The University Of California | Method for controlling blood pressure |
US4959358A (en) | 1983-06-06 | 1990-09-25 | Beth Israel Hospital Assn. | Drug administration |
JPS60161924A (en) | 1984-02-01 | 1985-08-23 | Fujisawa Pharmaceut Co Ltd | Composition for lung absorption |
EP0170715B1 (en) * | 1984-08-09 | 1988-04-13 | Inge Brugger | Nebulizer |
JPS6248634A (en) | 1985-07-23 | 1987-03-03 | Mochida Pharmaceut Co Ltd | Novel amino acid composition, production thereof and pharmaceutical composition containing said amino acid composition |
DE10006167B4 (en) * | 2000-02-11 | 2009-07-23 | Abb Schweiz Ag | breakers |
DE10032433A1 (en) * | 2000-07-04 | 2002-01-17 | H A N D Gmbh | Ground space monitoring procedures |
-
1987
- 1987-08-18 DE DE8787307276T patent/DE3779221D1/en not_active Expired - Lifetime
- 1987-08-18 EP EP87307276A patent/EP0257956B2/en not_active Expired - Lifetime
- 1987-08-18 AT AT87307276T patent/ATE76311T1/en not_active IP Right Cessation
- 1987-08-18 ES ES87307276T patent/ES2032831T5/en not_active Expired - Lifetime
- 1987-08-19 CA CA000544836A patent/CA1292182C/en not_active Expired - Fee Related
- 1987-08-19 JP JP62207361A patent/JP2573959B2/en not_active Expired - Fee Related
-
1992
- 1992-07-21 GR GR920401572T patent/GR3005238T3/el unknown
-
1993
- 1993-09-27 US US08/128,058 patent/US6099517A/en not_active Expired - Fee Related
-
2000
- 2000-04-19 US US09/552,199 patent/US6402733B1/en not_active Expired - Fee Related
-
2002
- 2002-06-10 US US10/171,562 patent/US20020193730A1/en not_active Abandoned
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
US4771769A (en) * | 1982-12-20 | 1988-09-20 | Schering Corporation | Hand held metered spray dispenser |
US4860738A (en) * | 1982-12-20 | 1989-08-29 | Schering Corporation | Hand held metered spray dispenser |
US4613500A (en) * | 1983-03-09 | 1986-09-23 | Teijin Limited | Powdery pharmaceutical composition for nasal administration |
US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
US4699136A (en) * | 1983-12-22 | 1987-10-13 | Krauser Robert S | Method and apparatus for treating ailments |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US4590003A (en) * | 1984-03-23 | 1986-05-20 | Oncogen | Platelet related growth regulator |
US4645828A (en) * | 1984-03-23 | 1987-02-24 | Oncogen | Platelet related growth regulator |
US4628045A (en) * | 1984-08-09 | 1986-12-09 | Immunetech Pharmaceuticals | Immunotherapeutic antiallergic polypeptide agents which bind to basophil immunoglobin Fc receptors |
US4659358A (en) * | 1985-03-19 | 1987-04-21 | Emhart Industries, Inc. | Mould arrangement of a glassware forming machine |
US6099517A (en) * | 1986-08-19 | 2000-08-08 | Genentech, Inc. | Intrapulmonary delivery of polypeptide growth factors and cytokines |
US4710305A (en) * | 1986-12-29 | 1987-12-01 | Conoco Inc. | Processes and oxidizing agents for oxidizing sulfide ion to innocuous, soluble sulfur species |
US5284656A (en) * | 1991-03-15 | 1994-02-08 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030222364A1 (en) * | 2002-03-20 | 2003-12-04 | Jackson Blair C. | Method and apparatus for producing dry particles |
US20040009231A1 (en) * | 2002-03-20 | 2004-01-15 | Advanced Inhalation Research, Inc. | hGH (human growth hormone) formulations for pulmonary administration |
US20050163725A1 (en) * | 2002-03-20 | 2005-07-28 | Blizzard Charles D. | Method for administration of growth hormone via pulmonary delivery |
US20060039987A1 (en) * | 2002-03-20 | 2006-02-23 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
WO2006055950A1 (en) * | 2004-11-18 | 2006-05-26 | Nektar Therapeutics | Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents |
Also Published As
Publication number | Publication date |
---|---|
JPS6351868A (en) | 1988-03-04 |
EP0257956B1 (en) | 1992-05-20 |
GR3005238T3 (en) | 1993-05-24 |
US6402733B1 (en) | 2002-06-11 |
DE3779221D1 (en) | 1992-06-25 |
CA1292182C (en) | 1991-11-19 |
US6099517A (en) | 2000-08-08 |
JP2573959B2 (en) | 1997-01-22 |
EP0257956B2 (en) | 2000-11-22 |
EP0257956A3 (en) | 1989-04-19 |
ES2032831T5 (en) | 2001-02-16 |
ES2032831T3 (en) | 1993-03-01 |
EP0257956A2 (en) | 1988-03-02 |
ATE76311T1 (en) | 1992-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6402733B1 (en) | Intrapulmonary delivery of polypeptide growth factors and cytokines | |
KR100652532B1 (en) | Flow resistance modulated aerosolized active agent delivery | |
KR100620338B1 (en) | Aerosolized active agent delivery | |
US7300919B2 (en) | Pulmonary delivery of active fragments of parathyroid hormone | |
US20110268668A1 (en) | Process for nebulizing aqueous compositions containing highly concentrated insulin | |
US20030064032A1 (en) | Process for nebulizing aqueous compositions containing highly concentrated insulin | |
JP2002500192A (en) | Method for administering AspB28-human insulin | |
AU2003218306A1 (en) | Method for administration of growth hormone via pulmonary delivery | |
WO2002094283A2 (en) | Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |